Dr. Abbas received his medical degree in India, completed training in Pathology at Harvard and joined the faculty at Harvard Medical School and the Brigham and Women’s Hospital, where he rose to become Professor of Pathology and Head of the Immunology Research Division. In 1999, after twenty years on the Harvard faculty, he moved to the University of California at San Francisco as Professor and Chairman of the Department of Pathology. Dr. Abbas has received several honors, including election to the Institute of Medicine of the National Academy of Sciences, election as a Fellow of the American Academy of Arts and Sciences, and the Rous-Whipple Award and Robbins Educator Award of the American Society of Investigative Pathology. He has served as one of the founding Editors and Associate Editor of Immunity, Associate Editor and Section Editor for The Journal of Immunology, Associate Editor of Cell, Consulting Editor of The Journal of Clinical Investigation, and founding Editor of the Annual Review of Pathology: Mechanisms of Disease. From 2011-2013, he was the President of the Federation of Clinical Immunology Societies (FOCIS). Dr. Abbas’ research interests are in Immunology, with a focus on the control of immune responses and the causes of autoimmunity. His laboratory has used experimental models to analyze the generation and maintenance of regulatory T cells. He has published over 190 peer-reviewed papers and invited reviews, and is the author of four widely read textbooks, two in Immunology and two in Pathology. He has taught Immunology at Harvard Medical School and UCSF, and has organized and conducted Immunology courses worldwide.
SCIENTIFIC ADVISORY BOARD
Copyright © APPLIED MOLECULAR TRANSPORT, LLC 2016. All rights reserved.
Dr. Hanauer is currently the Clifford Joseph Barborka Professor of Medicine in the Northwestern University Feinberg School of Medicine and Medical Director of the Digestive Health Center of Northwestern Medicine. He moved to Northwestern in January 2014 after 30 years on the faculty of the University of Chicago Pritzker School of Medicine where he led the Inflammatory Bowel Disease Center from 1983-2000 and was Chief of the Section of Gastroenterology, Hepatology and Nutrition from 2000-2013. He is a Fellow of the American College of Gastroenterology and is currently President of the American College of Gastroenterology, and served as Chairman of the Section of Immunology, Infection and Inflammatory Bowel Disease; Chairman of the Section of Clinical Practice; and as Councilor for Clinical Research. He is currently Associate Editor for inflammatory bowel disease for the journal Clinical Gastroenterology and Hepatology and is on the editorial board for numerous other journals including Inflammatory Bowel Diseases. He is ex-Chairman and a current member of the International Organization for Inflammatory Bowel Diseases and is co-Chairman for the Crohn’s and Colitis Foundation Advances in Inflammatory Bowel Disease where he has served as such for over a decade. He also served as a member and Chair of the Food and Drug Administration Advisory Committee for Gastrointestinal Disorders and continues to provide ad hoc consultation for the FDA. He has served on the Gastroenterology Specialty Board for the American Board of Internal Medicine. Dr. Hanauer has published over 300 articles related to inflammatory bowel disease and has cared for thousands of patients with ulcerative colitis and Crohn’s disease.
Stephen B. Hanauer, MD
Tom Boone is an experienced bench scientist and manager having served a 28 year career with Amgen. Tom received his graduate degrees from UC Davis and UCLA and joined Amgen as a research associate cloning, sequencing, expressing, and purifying recombinant proteins. He was a key scientist in the discovery and development of Neupogen, Neulasta, and Nplate. During the late 80’s and throughout the 1990’s, Tom worked in process development as a scientist and director and developed or oversaw the development of many of the processes implemented at Amgen. Tom then headed the expression, purification, and characterization groups within Amgen's research group which went on to become the Protein Science group. Tom retired from Amgen in 2009 as VP, Protein Sciences overseeing a biologics R&D team of over 300 researchers across five sites. After he left Amgen, Tom started his own consulting company as well as a company to develop veterinary products. He also helped several other companies get started. Currently he consults or is a scientific advisor for than 10 companies.
Abul Abbas, MBBS
University of California San Francisco
Dr. Richard S. Blumberg trained in internal medicine (The New York Hospital), infectious diseases (Massachusetts General Hospital) and gastroenterology & hepatology (Brigham & Women’s Hospital). He is currently Senior Physician in Medicine and Gastroenterology at Brigham and Women’s Hospital (BWH) where he leads the Division of Gastroenterology, Hepatology and Endoscopy, is Professor of Medicine at Harvard Medical School and co-Director of the Harvard Digestive Diseases Center. In addition, Dr. Blumberg serves on the Executive Advisory Committee of the Department of Medicine and is the Chair of the Biomedical Research Institute at BWH. He has served as a member of the Immunology Sciences Study Section of NIAID, a member on the National Commission of Digestive Diseases of the NIDDK, scientific consultant to the Human Microbiome Project (NHGRI), a member of the Vaccine Branch External Advisory Board (NCI), Chair of the External Scientific Consultants for the Intestinal Stem Cell Consortium Initiative (NIDDK) and is currently on the Board of Scientific Councilors (NIAID). He served as the Chair of the National Scientific Advisory Committee of the Crohn’s & Colitis of America (2002-2005) and President of the Society for Mucosal Immunology (2007-2009). Dr. Blumberg is an elected member of the American Association of Clinical Investigation and the Association of American Physicians and the recipient of a MERIT Award from the NIH (2005), the William Beaumont Prize from the American Gastroenterological Association (2012) and the Distinguished Scientific Achievement Award from the Crohn’s and Colitis Foundation of America (2012). He is an NIH-funded investigator whose research program focuses on mucosal immunology and was Scientific Founder, Syntonix Pharmaceuticals (now Biogen-Hemophilia) that developed long-acting therapeutic agents successful in the treatment of chronic diseases such as hemophilia A and B.
Richard S. Blumberg, MD
Harvard Medical School